# US 2010/0168071 A1 · Extended estrogen dosing contraceptive regimen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168071 A1
- Document ID: US20100168071A1
- Status: Published application
- Kind: A1
- Application number: 12/722,967
- Filed: 2010-03-12
- Published: 2010-07-01
- Earliest claimed: 2005-04-22
- Assignees: Warner Chilcott Company, LLC
- Inventors: Roger M. Boissonneault
- Web page: https://patentgrep.com/patent/US20100168071A1

## CPC

- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61P 15/18: Feminine contraceptives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A contraceptive kit comprising a package containing daily dosages of: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 22 to about 26 days; (b) a second composition containing an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 2 to about 3 days and an optional third composition that is a placebo provided that (i) if estrogen administration is continuous then the first composition is administered for 25 to 26 days, the second composition is administered for 2 to 3 days and no third composition is administered and (ii) if estrogen administration is not continuous then the first composition is administered for 22 to 24 days, the second composition is administered for 2 to 3 days and the third composition is administered for 1 to 4 days. The total cycle length is 28 days, with the first composition administered on day 1 of the menstrual cycle, defined as the first day of menstrual bleeding, or on the first Sunday after the first day of the menstrual cycle.

## Claims

### Claim 1

A contraceptive kit comprising a package containing daily dosages of:
(a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol;
(b) a second composition containing an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol and substantially free of a progestin; an
(c) an optional third composition that is a placebo,
wherein the package contains 22 to 26 daily dosages of the first composition, 2 to 3 daily dosages of the second composition, optionally 1 to 4 daily dosages of the third composition, and a total amount of daily dosages of the first composition, second composition and optional third composition, when present, is 28 and further provided that (i) when the kit contains no third composition then the package contains 25 to 26 monophasic daily dosages of the first composition and 2 to 3 daily dosages of the second composition and (ii) when the kit contains 1 to 4 daily dosages of the third composition then the package contains 22 to 24 daily dosages of the first composition and 2 to 3 daily dosages of the second composition.

### Claim 2 (depends on 1)

The kit according to claim 1, wherein the package contains 25 to 26 daily dosages of the first composition and 2 to 3 daily dosages of the second composition.

### Claim 3 (depends on 1)

The kit according to claim 1, wherein the package contains 22 to 24 daily dosages of the first composition, 2 to 3 daily dosages of the second composition and 1 to 4 daily dosages of the third composition.

### Claim 4 (depends on 1)

The kit according to claim 1, wherein the progestin is selected from the group consisting of norethindrone acetate, drospirenone, trimegestone, norethindrone, levonorgestrel, desogestrel, 3-ketodesogestrel, gestodene, demogestone, dydrogesterone, medrogestone, medroxy progesterone, esters and mixtures thereof.

### Claim 5 (depends on 1)

The kit according to claim 1, wherein the estrogen is selected from the group consisting of ethinyl estradiol, 17-β-estradiol, conjugated estrogens, mestranol, estrone, and esters, prodrugs and salts thereof.

### Claim 6 (depends on 2, 3)

The kit according to any one of claims 2 and 3, wherein the progestin in the first composition is norethindrone acetate.

### Claim 7 (depends on 6)

The kit according to claim 6, wherein the amount of norethindrone acetate in the first composition is about 1 mg.

### Claim 8 (depends on 2, 3)

The kit according to any one of claims 2 and 3, wherein the estrogen in the first and second composition is ethinyl estradiol.

### Claim 9 (depends on 8)

The kit according to claim 8, wherein the amount of ethinyl estradiol in the first and second composition is about 15 mcg.

### Claim 10 (depends on 2, 3)

The kit according to any one of claims 2 and 3, wherein (i) the first composition contains about 1.0 mg of norethindrone acetate and about 15 mcg of ethinyl estradiol, and (ii) the second composition contains about 15 mcg of ethinyl estradiol.

### Claim 11 (depends on 1)

The kit according to claim 1, wherein the placebo contains about 75 mg of ferrous fumarate.
